0001309014-13-000502.txt : 20130710 0001309014-13-000502.hdr.sgml : 20130710 20130710113756 ACCESSION NUMBER: 0001309014-13-000502 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130710 FILED AS OF DATE: 20130710 DATE AS OF CHANGE: 20130710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 13961145 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 6-K 1 htm_7846.htm LIVE FILING Teva Pharmaceutical Industries Ltd.  - Form 6-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 10, 2013

Commission File Number: 0-16174

Teva Pharmaceutical Industries Ltd.
———————————————————————————————————
(Translation of registrant’s name into English)
 
Israel
———————————————————————————————————
(Jurisdiction of incorporation or organization)
 
5 Basel Street, P.O. Box 3190
Petach Tikva 49131 Israel
———————————————————————————————————
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  [x] Form 20-F    [ ] Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  [ ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  [ ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:  [ ] Yes    [x] No
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):    n/a 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
    Teva Pharmaceutical Industries Ltd.
     
Date: 07/10/2013 By: Eyal Desheh
  Name:  Eyal Desheh
  Title: Chief Financial Officer
     
EXHIBIT INDEX

Exhibit No.   Description
 
99.1   Teva Completes Acquisition of MicroDose
     
EX-99.1 2 exhibit1.htm EX-99.1 Exhibit  EX-99.1

Teva Completes Acquisition of MicroDose

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has completed the acquisition of effectively 100% of the outstanding shares of MicroDose for $40 million on July 8, 2013. The transaction was funded with cash on hand.